Kala Bio Inc (NAS:KALA)
$ 6.89 -0.045 (-0.65%) Market Cap: 31.97 Mil Enterprise Value: 16.60 Mil PE Ratio: 0 PB Ratio: 4.68 GF Score: 44/100

Q2 2019 Kala Pharmaceuticals Inc Earnings Call Transcript

Aug 06, 2019 / 12:00PM GMT
Release Date Price: $219 (-13.27%)
Operator

Good morning, and welcome to Kala Pharmaceuticals Second Quarter 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to turn the call over to Mary Reumuth, Chief Financial Officer for Kala Pharmaceuticals. Please proceed.

Mary Reumuth
Kala Pharmaceuticals, Inc. - CFO & Treasurer

Thank you, operator, and thank you all for participating in today's call. Joining me from the company are Mark Iwicki, Chairman, President and Chief Executive Officer; Kim Brazzell, Chief Medical Officer; and Todd Bazemore, Chief Operating Officer.

Today's call is being webcast live and the webcast link can be found in the Investors & Media section on the Kala corporate website at kalarx.com.

During this call, we will be referring to non-GAAP financial measures, which are not prepared in accordance with generally accepted accounting principles. A reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures is available in our press release issued today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot